Merck & Co. and Gilead Sciences have secured U.S. Food and Drug Administration approval for Keytruda (pembrolizumab) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy (sacituzumab govitecan-hziy), as first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have a PD-L1 combined positive score of at least 10. The June 24, 2026 approval is based on the Phase 3 ASCENT-04/KEYNOTE-D19 trial and establishes the first approved pairing of a PD-1 inhibitor with a Trop-2-directed antibody-drug conjugate in advanced triple-negative breast cancer.
Why does replacing chemotherapy with a Trop-2 antibody-drug conjugate matter in first-line TNBC?
The most important change is not the addition of pembrolizumab, which was already part of the standard first-line approach for PD-L1-positive advanced triple-negative breast cancer. It is the replacement of conventional chemotherapy with sacituzumab govitecan-hziy as the cytotoxic backbone. That turns an antibody-drug conjugate previously associated mainly with later-line treatment into an initial therapy used before the tumor has been exposed to systemic treatment for advanced disease.
This is not a chemotherapy-free regimen in the strict biological sense. Sacituzumab govitecan-hziy carries SN-38, an active metabolite of irinotecan, directly toward Trop-2-expressing cells and can also affect nearby tumor cells through payload release. The distinction is therefore about delivery and selectivity rather than the disappearance of cytotoxic therapy. The practical objective is to improve the depth and durability of tumor control while avoiding some of the cumulative toxicities and discontinuation patterns associated with standard taxane-based or platinum-based chemotherapy.
That distinction matters in metastatic triple-negative breast cancer because the first treatment decision often determines how long disease can be controlled before subsequent therapy is required. A substantial proportion of patients do not reach later lines of treatment because of rapid progression, declining performance status or treatment-related complications. Moving an active antibody-drug conjugate forward may therefore expose more patients to its benefit, but it also removes sacituzumab govitecan-hziy from its familiar role as a later-line option and creates new uncertainty about what should follow after progression.
How strong is the ASCENT-04 evidence supporting a new first-line treatment backbone?
ASCENT-04/KEYNOTE-D19 enrolled 443 previously untreated patients with locally advanced or metastatic triple-negative breast cancer and PD-L1 combined positive scores of at least 10. Participants were randomly assigned to sacituzumab govitecan-hziy plus pembrolizumab or to pembrolizumab combined with investigator-selected chemotherapy consisting of paclitaxel, nab-paclitaxel, or gemcitabine and carboplatin. This active-control design is a major strength because the experimental regimen was tested against an established first-line immunochemotherapy standard rather than against an outdated or clinically weak comparator.
Median progression-free survival reached 11.2 months with sacituzumab govitecan-hziy plus pembrolizumab, compared with 7.8 months for pembrolizumab plus chemotherapy. The hazard ratio of 0.65 represents a 35% reduction in the risk of disease progression or death. The confirmed objective response rate was 61% versus 55%, while median response duration was 16.5 months versus 9.2 months. The response-rate difference is modest, but the longer duration suggests the main advantage may be sustained control rather than a dramatic increase in the number of patients who initially respond.
The trial was open label, which can influence treatment decisions, adverse-event reporting and patient-reported outcomes. However, the primary progression-free survival endpoint was assessed through blinded independent central review, reducing the risk that investigator awareness alone drove the result. The larger limitation is that overall survival data remain immature. Patients in the control group could cross over to sacituzumab govitecan-hziy after progression, an ethically understandable feature that may make a later survival difference harder to detect. The approval therefore rests on a strong progression-free survival result, but the definitive effect on lifespan remains unresolved.
What does the safety profile reveal about the trade-off between ADC therapy and chemotherapy?
The new combination should not be interpreted as a low-toxicity alternative. Grade 3 or higher treatment-emergent adverse events occurred in roughly seven out of ten patients in both treatment groups. In the sacituzumab govitecan-hziy arm, the most frequent severe events included neutropenia and diarrhea. The product carries a boxed warning for severe neutropenia and severe diarrhea, and treatment requires blood-count monitoring, supportive care, dose interruptions and, for higher-risk patients, consideration of growth-factor prophylaxis.
The nature of toxicity differed from the chemotherapy control. Severe anemia and thrombocytopenia were more prominent with chemotherapy plus pembrolizumab, while gastrointestinal toxicity, nausea, alopecia and diarrhea were more prominent with the antibody-drug conjugate combination. Serious treatment-emergent adverse events were numerically more frequent with sacituzumab govitecan-hziy plus pembrolizumab, yet treatment discontinuation because of adverse events was lower at 12% compared with 31% in the chemotherapy arm. That contrast suggests toxicity remained substantial but was often manageable without permanently abandoning therapy.
The safety balance will depend heavily on patient selection and clinic experience. Patients with reduced UGT1A1 activity can face greater hematologic toxicity from sacituzumab govitecan-hziy, while pembrolizumab adds the possibility of immune-mediated complications affecting the lungs, liver, bowel, endocrine organs and other systems. The regimen combines two well-characterized safety profiles rather than introducing an unexpected new signal, but real-world use will involve older patients, patients with comorbidities and patients with less physiologic reserve than many clinical-trial participants.
How will PD-L1 testing determine which patients can receive the newly approved regimen?
Eligibility depends on a PD-L1 combined positive score of at least 10 measured with an FDA-authorized test. This preserves the biomarker threshold already used for pembrolizumab-based first-line treatment in advanced triple-negative breast cancer, making the diagnostic pathway familiar to oncology centers. It also means the approval does not eliminate the need for timely tissue acquisition, validated testing and reliable pathology turnaround before treatment begins.
The threshold creates a clear regulatory boundary but not a perfect biological division. PD-L1 expression can vary across tumor sites, change over time and be affected by specimen quality and sampling. A result below 10 excludes a patient from this pembrolizumab combination even though the tumor may still express Trop-2 and remain sensitive to sacituzumab govitecan-hziy. The FDA’s parallel first-line approval of Trodelvy monotherapy for patients who are not candidates for PD-1 or PD-L1 therapy partly addresses the broader population, but treatment selection will still require careful distinction between biomarker status, immunotherapy eligibility and prior treatment history.
The growing use of pembrolizumab in high-risk early-stage triple-negative breast cancer adds another unresolved issue. More patients entering the metastatic setting may already have received checkpoint inhibition before or after surgery. Clinicians will need more evidence on the benefit of restarting pembrolizumab with an antibody-drug conjugate after prior perioperative exposure, particularly when recurrence occurs relatively soon after treatment. A broad label can define who is eligible, but it cannot answer every sequencing question created by an evolving earlier-stage standard of care.
Can Keytruda Qlex materially reduce administration burden in an infusion-intensive regimen?
Keytruda Qlex offers a subcutaneous formulation of pembrolizumab that can be administered in about one minute every three weeks or two minutes every six weeks, compared with a 30-minute intravenous pembrolizumab infusion. That flexibility can reduce time associated with the immunotherapy component, improve scheduling and provide an alternative for patients with difficult venous access. It also gives treatment centers a choice between intravenous Keytruda and subcutaneous Keytruda Qlex without changing the core checkpoint-inhibition strategy.
The operational benefit is real but limited by the rest of the regimen. Trodelvy remains an intravenous infusion given on days 1 and 8 of a 21-day cycle, with premedication, observation and laboratory monitoring requirements. A subcutaneous pembrolizumab dose therefore does not transform the combination into a brief outpatient injection regimen or remove the need for infusion capacity. It may shorten one component of a complex visit, but the total chair time and staffing benefit will vary according to how each oncology center schedules Trodelvy administration.
For Merck & Co., inclusion of Keytruda Qlex broadens adoption flexibility and supports the migration of eligible indications to a faster formulation. For providers, the value proposition will depend on reimbursement, workflow and whether the time saved on pembrolizumab meaningfully offsets the administrative steps required for sacituzumab govitecan-hziy. Convenience may support uptake at the margin, but clinical efficacy and tolerability will remain the primary determinants of regimen choice.
What commercial impact could first-line use have for Gilead Sciences and Merck & Co.?
The approval is commercially more transformative for Gilead Sciences because it moves Trodelvy into a larger and earlier treatment setting. Trodelvy generated approximately $1.4 billion in 2025 sales, and first-quarter 2026 revenue rose 37% to $402 million. First-line use can expand the eligible patient pool, increase the average duration of treatment and strengthen the drug’s position as a central oncology growth asset rather than a therapy reserved for heavily pretreated disease.
For Merck & Co., the approval reinforces pembrolizumab as the immunotherapy anchor while changing the partner attached to it. Combined Keytruda and Keytruda Qlex sales reached $31.68 billion in 2025 and $8.03 billion in the first quarter of 2026. The strategic value is therefore less about opening an entirely new tumor market and more about defending the franchise’s role as treatment backbones evolve from traditional chemotherapy toward antibody-drug conjugates and other targeted payload platforms.
Commercial expansion will not be automatic. A regimen combining a leading checkpoint inhibitor with an antibody-drug conjugate may face close payer scrutiny because both components are high-value oncology products and overall survival remains immature. Payers and health systems will weigh the 3.4-month median progression-free survival improvement, longer response duration and lower discontinuation rate against acquisition costs, supportive-care requirements and uncertain downstream sequencing. Strong guideline positioning can accelerate use, but reimbursement policy and institutional pathways will determine how quickly the approval becomes routine practice.
What could prevent the combination from becoming the default PD-L1-positive TNBC regimen?
The direct comparison against pembrolizumab plus chemotherapy gives the regimen a credible path to becoming a preferred first-line option. It has already received high-level guideline support, and the FDA approval removes the principal regulatory barrier in the United States. The combination’s longer progression-free survival and more durable responses are likely to make it difficult for clinicians to ignore when treating eligible patients with adequate marrow and gastrointestinal reserve.
However, overall survival remains the most important unanswered efficacy question. The crossover design may dilute a survival difference, but it also reflects a clinically relevant reality in which patients can receive sacituzumab govitecan-hziy after progression. If mature data show little or no overall survival advantage, treatment decisions may depend more heavily on quality of life, toxicity, treatment-free intervals and cost. Progression-free survival is meaningful in aggressive metastatic disease, but its commercial and clinical value becomes stronger when supported by longer survival or clearly better patient-reported outcomes.
The regimen also creates a sequencing challenge. Once sacituzumab govitecan-hziy is used first, evidence is limited on the optimal second-line approach and on the effectiveness of another antibody-drug conjugate with a related topoisomerase payload. Chemotherapy, targeted treatment for patients with actionable germline mutations, clinical trials and other emerging agents will remain relevant, but the order of use is likely to vary until prospective sequencing data mature.
What should clinicians, regulators and industry observers watch after the FDA approval?
The first priority is mature overall survival from ASCENT-04/KEYNOTE-D19. Duration of response, progression-free survival after subsequent treatment and patient-reported outcomes will help determine whether earlier use produces benefits that extend beyond the first radiographic progression. Subgroup analyses will also be important for patients with de novo metastatic disease, recurrent disease after perioperative therapy, different chemotherapy histories and varying levels of PD-L1 expression within the eligible population.
Real-world safety will be equally important. Oncology practices will need to track neutropenia, diarrhea, dose reductions, growth-factor use, hospitalizations and treatment discontinuation outside the controlled environment of a Phase 3 trial. The lower discontinuation rate versus chemotherapy is encouraging, but it must be confirmed across more diverse populations and community settings where supportive-care capacity differs.
The broader strategic signal is already clear. Antibody-drug conjugates are moving from salvage treatment into the first line and are beginning to replace, rather than merely supplement, conventional chemotherapy backbones. The Keytruda and Trodelvy approval is therefore more than an incremental label expansion. It is an early test of whether targeted cytotoxic delivery can become the default partner for immunotherapy in aggressive solid tumors, and whether the added clinical value is sufficient to justify the complexity and cost of using two premium biologic platforms together.
Merck and Gilead secure FDA approval for a new ADC-immunotherapy backbone in advanced TNBC added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →